Should all patients starting on ADT be on a statin too?

A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …

Combining ADT and salvage radiation therapy improves outcomes

For the first time, a randomized clinical trial (GETUG-AFU 16) has proved that adding a short course of androgen deprivation therapy (ADT) to salvage radiation therapy (sRT) improves the progression-free survival over sRT alone. … READ MORE …

Adding docetaxel to ADT and radiation therapy for high-risk prostate cancer

Earlier today, at the annual meeting of the American Society of Clinical Oncology (ASCO), we were given the results of RTOG 0521 — a large, randomized trial of adding docetaxel chemotherapy to androgen deprivation therapy (ADT) and radiation therapy for men with high-risk prostate cancer. … READ MORE …

Low dose rate brachytherapy monotherapy across risk groups

New registry data from the Cleveland Clinic shows good oncological control with low dose rate brachytherapy (LDRBT) monotherapy, at least for low-risk and low  intermediate-risk groups. This is the first time I’ve seen LDRBT monotherapy data for higher-risk groups. … READ MORE …

Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer

It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …

New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,322 other followers